Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8725779 | 0.89 | ALOX5 (0.65) | ALOX5BCHEACHENOX1AHR | |
| SCHEMBL6971831 | 0.84 | BCHE (0.49) | ALOX5BCHEACHENOX1MAPT | |
| Phenoxazine SCHEMBL7862 | 0.81 | ALOX5 (1.00) | ALOX5LMNAHTR2BHTR7MAPT | |
| Phenoxazine SCHEMBL28844098 | 0.81 | ALOX5 (1.00) | ALOX5LMNAHTR2BHTR7MAPT | |
| Phenoxazine SCHEMBL29355714 | 0.81 | ALOX5 (1.00) | ALOX5LMNAHTR2BHTR7MAPT | |
| Phenoxazine SCHEMBL6310178 | 0.81 | ALOX5 (1.00) | ALOX5LMNAHTR2BHTR7MAPT | |
| SCHEMBL11536640 | 0.81 | ALOX5 (0.65) | ALOX5AHRLMNAHTR2BHTR7 | |
| SCHEMBL172370 | 0.80 | LMNA (0.58) | ALOX5LMNATP53MAPTCHEK1 | |
| SCHEMBL9967368 | 0.80 | LMNA (0.61) | ALOX5LMNATP53MAPTCHEK1 | |
| SCHEMBL29753145 | 0.80 | LMNA (0.61) | ALOX5LMNATP53MAPTCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-10-26 | — | — | US | claimed |
| WO-2006094207-A2 | SUBSTITUTED PHENOXAZINES AND ACRIDONES AS INHIBITORS OF AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-09-08 | — | — | WO | claimed |
| US-20230192719-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-114014883-A | Organic boron compound and application thereof in organic electroluminescent device | 湖北尚赛光电材料有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-10-26 | — | — | US | disclosed |
| WO-2006094207-A2 | SUBSTITUTED PHENOXAZINES AND ACRIDONES AS INHIBITORS OF AKT | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-09-08 | — | — | WO | disclosed |
| US-4132794-A | 10-Imidoylacridan compositions | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
| US-4115571-A | DIURETICS, SMOOTH MUSCLE RELAXANTS, ANTITHROMBOGENIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4094981-A | SMOOTH MUSCLE RELAXANT EMPLOYING 10-IMIDOYLACRIDANS | MEAD JOHNSON & COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4077959-A | DIURETICS, SMOOTH MUSCLE RELAXANTS, ANTITHROMBOGENIC | MEAD JOHNSON & COMPANY (US) | 1978-03-07 | — | — | US | disclosed |
| US-4046891-A | Smooth muscle relaxant process employing 10-imidoylphenoxazines | MEAD JOHNSON & COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-3962252-A | 10-IMIDOYLACRIDANS | MEAD JOHNSON & COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3946004-A | DIURETICS, MUSCLE RELAXANTS, ANTITHROMBOGENIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192719-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | OR10J3, CRY1, RPS19 | ALOX5 2723/4885BCHE 4282/4885ACHE 3404/4885 |
| US-20060241108-A1 | Substituted phenoxazines and acridones as inhibitors of AKT | AKT1S1, AKT3, PIK3CA | ALOX5 1732/4885BCHE 4401/4885ACHE 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.